CVM

CEL-SCI Corporation (CVM) - 10-Q Summary

Business Context and Reporting Period

Company: CEL-SCI Corporation (CEL-SCI)
Reporting Period: Nine months ended June 30, 2025 (Q3 2025)
Business Overview: CEL-SCI is a late clinical-stage biotechnology company focused on developing Multikine, an investigational immunotherapy for head and neck cancer, and L.E.A.P.S. technology for rheumatoid arthritis. The company has no approved products and relies on equity financing to fund operations.
Stock Split: A 30-for-1 reverse stock split became effective on May 20, 2025. All share and per-share data in this filing have been retroactively adjusted.

Key Financial Metrics

Material Changes vs. Prior Period

• Reduced Net Loss: Net loss decreased by approximately $1.5 million (7%) compared to the prior year period, primarily due to a significant reduction in share-based compensation expenses ($2.1 million in 2025 vs. $4.1 million in 2024).
• Operating Expenses: Total operating expenses decreased by $1.45 million. Research and Development (R&D) expenses declined by $1.5 million, driven by lower stock-based compensation and reduced clinical study costs. General and Administrative (G&A) expenses remained relatively flat.
• Liquidity Position: Cash balances increased significantly from $384,652 in June 2024 to $1,792,856 in June 2025, supported by net proceeds of approximately $11.0 million from equity financings in December 2024, March 2025, and May 2025.
• Share Count: Weighted average shares outstanding increased significantly due to the reverse split adjustment and new issuances, rising from 1.72 million (2024) to 3.05 million (2025).

Outlook, Risks, and Management Commentary

• Going Concern Warning: The company explicitly states there is "substantial doubt about the Company's ability to continue as a going concern" due to recurring losses and future liquidity needs. Continued operations depend on raising additional capital.
• Capital Requirements: The estimated cost for the confirmatory registration study for Multikine is approximately $30 million. The company plans to raise funds through corporate partnerships, debt, or equity financings.
• Clinical Progress: Management highlights Phase III data showing a 73% 5-year survival rate for Multikine-treated patients in the target population (low PD-L1 expression) versus 45% for the control group. The FDA has indicated the company may proceed with a 212-patient confirmatory registration study.
• Subsequent Events:
  • July 14, 2025: Sold 1,500,000 shares at $3.82/share for gross proceeds of ~$5.7 million.
  • July 25, 2025: CEO and director purchased ~32,000 shares for ~$220,000.
  • July 4, 2025: Enactment of the "One Big Beautiful Bill Act" (OBBBA); impact on deferred taxes is being evaluated.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, due to material weaknesses previously disclosed in the 2024 10-K.

Investor Verification Checklist

• Cash Runway: Verify if the current cash balance ($1.8M) plus recent subsequent financing ($5.7M) is sufficient to fund the estimated $30M confirmatory study or if immediate additional fundraising is required.
• Equity Dilution: Assess the impact of the recent 30-for-1 reverse split and subsequent share issuances on existing shareholder ownership percentages.
• Internal Control Weaknesses: Review the specific material weaknesses in internal controls over financial reporting to understand the risk of future financial misstatements.
• Regulatory Pathway: Confirm the status of the FDA's agreement on the 212-patient confirmatory study design and the timeline for enrollment.
• Lease Obligations: Review the significant finance lease liabilities (~$8.5M total) and the requirement to maintain specific cash thresholds to avoid forfeiting deposits.